Prevalence of methicillin resistant Staphylococcus aureus (meca gene) among the patients admitted in intensive care unit.
Author(s): Priyanka Chauhan*, Prabhakar S. Bais, Nidhi Gupta
The present study was aimed to evaluate the prevalence of among the patients admitted in intensive care unit. The blood samples were processed which were already sent to microbiology department. Blood samples were collected in blood culture bottles containing the medium for the bacterial growth. After incubating the blood culture bottles containing medium and blood samples were plated on the solid medium and incubated for the bacterial growth. All the samples were subjected to grams staining and for identification of Staphylococcus aureus catalase test, coagulase test, oxidation/fermentation test, sugar fermentation test, Amino acid tests and urease test. CONS (27.34%) were the predominating species in all blood culture followed by Acinetobactor, E. coli and Staphylococcus aureus which are 24.10%, 13.67% and 13.31% respectively. Thirty one, 83.8%, MRSA strains were detected in the 37 S. aureus isolates obtained during the study period. Over all S. aureus isolation was obtained 37 (13.31%) of all 278 isolates from blood culture. More than 80% resistance was shown by gentamicin, oxacillin, amoxicillin and cefoxitin. All 31 strains were resistant to cifoxitin. More than 90% resistance was shown by gentamicin, ciprofloxacin and amoxicillin. More than 50% isolates were resistant to erythromycin. Vancomycin and Linezolide were 100% sensitive drugs against the MRSA isolates. More than 50% isolates were sensitive to clindamycin. Due to the ever increasing MRSA infection in hospitals, related cost and ailments and its spread in other patients and as well as in the community via the health care workers, every hospital or health care settings should survey the MRSA prevalence and follow the universal precautions, the most important one being washing hand with alcohol based soap after each patient care.
Share this article
International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.